Trimerising Polypeptides - A Platform Technology - Isis Project No 508
Trimerising polypeptides present a novel and cost effective protein engineering process which generates small, stable trimeric arrays.
Therapeutic Areas
- Cancer
- Immunotherapy
- Infectious diseases
- Diagnostics
- High throughput Screening
- Research on low-affinity receptors
- Collagen engineering
Background To The Oxford Invention
Trimerising polypeptides present a novel and cost effective protein engineering process which generates small, stable trimeric arrays. Compared to conventional technology, dramatic affinity increases are seen whilst allowing for additional molecules, such as cytotoxins or detection modules, to be fused to the other end of the trimers.
Market Potential
- Protein therapeutics in man
- Conversion of extracellular domains from low affinity receptors into trimeric arrays with antibody-like affinities
- Antibody-based diagnostic and high-throughput screening systems
- Collagen production
Commercialisation Opportunity
Isis Innovation is seeking commercial partners to exploit and further develop this novel and exciting platform technology. The strong patent position of this technology has resulted in an allowance in the US (08/737,629), and positive examination reports for pending patents in Europe (95918689.1), Canada (2190264) and Japan (7-529462).